US drug regulators have issued their first ever approval for a Chinese-developed innovative cancer treatment, marking a breakthrough for China’s emerging biotech sector.
The US Food and Drug Administration approved zanubrutinib, a treatment for mantle cell lymphoma, a rare kind of blood cancer, for use by patients who have received one prior therapy for the disease.
Chinese company BeiGene developed the treatment in Beijing under the name Brukinsa.
您已閱讀16%（450字），剩餘84%（2428字）包含更多重要資訊，訂閱以繼續探索完整內容，並享受更多專屬服務。